# Aruba Chemicals Export Opportunities (HS 28-38)

![Yugalinks](https://www.yugalinks.com/trade/yugalinks-logo-v3-dark-mode.webp)

> Yugalinks sector export playbook

Explore Aruba HS 28-38 chemicals export opportunities, product portfolio, buyer markets, growth signals, and diversification opportunities.

## Overview

- Exporter: Aruba (ABW)
- Sector: Chemicals
- HS chapters: HS 28-38
- Latest trade year: 2024
- Sector exports: $2.6M
- Products: 24
- Buyer markets: 11
- Average CAGR: +11.9%
- Global sector size: $289.1B

## Product portfolio

| Product | Global size | Your exports | Opportunity | CAGR | Markets | Share |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| HS 300490 - Medicaments: consisting of mixed or unmixed products n.e.s. in heading no. 3004, for therapeutic or prophylactic uses, packaged for retail sale | $118.1B | $1.1M | $34.5B | -14.1% | 7 | +0.0% |
| HS 300215 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, put up in measured doses or in forms or packings for retail sale | $81.2B | $441.4 | $31.1B | +17.0% | 2 | +0.0% |
| HS 300220 - Vaccines: for human medicine | $12.8B | $2.7K | $8.6B | +16.3% | 2 | +0.0% |
| HS 382499 - Chemical products, mixtures and preparations: n.e.c. heading 3824 | $11.7B | $18.6K | $7.8B | +8.3% | 4 | +0.0% |
| HS 330300 - Perfumes and toilet waters | $9.5B | $184.8K | $5.6B | -6.0% | 5 | +0.0% |
| HS 300214 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, mixed, put up in measured doses or in forms or packings for retail sale | $4.4B | $0.0 | $4.9B | +70.0% | 1 | +0.0% |
| HS 330499 - Cosmetic and toilet preparations: n.e.c. in heading no. 3304, for the care of the skin (excluding medicaments, including sunscreen or sun tan preparations) | $10.9B | $1.1M | $4.4B | +16.2% | 5 | +0.0% |
| HS 300212 - Blood, human or animal, antisera, other blood fractions and immunological products: antisera and other blood fractions | $8.5B | $289.3 | $4.3B | +10.7% | 1 | +0.0% |
| HS 382200 - Reagents: diagnostic or laboratory reagents on a backing and prepared diagnostic or laboratory reagents whether or not on a backing, other than those of heading no. 3002 or 3006: certified reference material | $8.7B | $7.8K | $2.7B | +2.4% | 3 | +0.0% |
| HS 300290 - Toxins, cultures of micro-organisms (excluding yeasts) and similar products | $4.3B | $5.9K | $2.4B | -19.3% | 3 | +0.0% |
| HS 300420 - Medicaments: containing antibiotics (other than penicillins, streptomycins or their derivatives), for therapeutic or prophylactic uses, packaged for retail sale | $3.8B | $34.6 | $2.0B | -19.3% | 1 | +0.0% |
| HS 290110 - Acyclic hydrocarbons: saturated | $916.4M | $136.0 | $1.3B | -88.4% | 1 | +0.0% |
| HS 300390 - Medicaments: (not containing antibiotics, hormones, alkaloids or their derivatives), for therapeutic or prophylactic uses, (not packaged for retail sale) | $1.8B | $63.1 | $1.2B | -15.1% | 1 | +0.0% |
| HS 330590 - Hair preparations: n.e.s. in heading no. 3305 | $1.8B | $32.8K | $755.4M | -10.1% | 2 | +0.0% |
| HS 300432 - Medicaments: containing corticosteroid hormones, their derivatives or structural analogues (but not containing antibiotics), for therapeutic or prophylactic uses, packaged for retail sale | $1.9B | $11.9 | $746.4M | +3.3% | 1 | +0.0% |
| HS 340220 - Washing and cleaning preparations: surface-active, whether or not containing soap (excluding those of heading no. 3401), put up for retail sale | $1.1B | $358.2 | $719.0M | +58.1% | 1 | +0.0% |
| HS 284440 - Radioactive elements, isotopes, compounds, n.e.c. in heading no. 2844 alloys, dispersions (including cermets), ceramic products and mixtures containing these elements, isotopes or compounds: radioactive residues | $927.2M | $615.7 | $685.2M | -6.4% | 1 | +0.0% |
| HS 381800 - Chemical elements: doped for use in electronics, in the form of discs, wafers or similar forms: chemical compounds doped for use in electronics | $1.5B | $1.0K | $645.9M | +65.2% | 1 | +0.0% |
| HS 340600 - Candles, tapers and the like | $1.0B | $61.3 | $640.9M | +1.6% | 1 | +0.0% |
| HS 300439 - Medicaments: containing hormones (but not insulin), adrenal cortex hormones or antibiotics, for therapeutic or prophylactic uses, packaged for retail sale | $899.8M | $291.3 | $570.1M | -6.8% | 1 | +0.0% |
| HS 382319 - Industrial monocarboxylic fatty acids: acid oils from refining: (other than stearic acid, oleic acid or tall oil fatty acids) | $1.1B | $8.9 | $501.2M | -0.5% | 1 | +0.0% |
| HS 340130 - Organic surface-active products and preparations for washing the skin, in the form of liquid or cream and put up for retail sale, whether or not containing soap | $774.1M | $51.0K | $446.3M | +56.6% | 1 | +0.0% |
| HS 300590 - Wadding, gauze, bandages and similar articles: (excluding adhesive dressings), impregnated or coated with pharmaceutical substances, packaged for retail sale | $926.9M | $0.9 | $409.9M | -26.9% | 1 | +0.0% |
| HS 370790 - Photographic goods: chemical preparations other than sensitised emulsions, put up in measured portions or put up for retail sale in a form ready for use | $478.9M | $3.3K | $380.9M | +487.4% | 1 | +0.0% |

## Best markets

- USA, Puerto Rico and US Virgin Islands (USA): $78.3B calculated opportunity across 21 products.
- Netherlands (NLD): $19.6B calculated opportunity across 10 products.
- United Kingdom (GBR): $5.6B calculated opportunity across 3 products.
- Canada (CAN): $5.3B calculated opportunity across 3 products.
- Mexico (MEX): $3.8B calculated opportunity across 3 products.
- Saudi Arabia (SAU): $1.4B calculated opportunity across 3 products.
- Spain (ESP): $1.3B calculated opportunity across 1 products.
- China, Hong Kong Special Administrative Region (HKG): $813.4M calculated opportunity across 1 products.
- Colombia (COL): $443.6M calculated opportunity across 1 products.
- United Arab Emirates (ARE): $373.1M calculated opportunity across 1 products.
- France (FRA): $360.1M calculated opportunity across 1 products.

## Growth stars

- HS 370790: +487.4% average CAGR, $380.9M calculated opportunity.
- HS 300214: +70.0% average CAGR, $4.9B calculated opportunity.
- HS 381800: +65.2% average CAGR, $645.9M calculated opportunity.
- HS 340220: +58.1% average CAGR, $719.0M calculated opportunity.
- HS 340130: +56.6% average CAGR, $446.3M calculated opportunity.
- HS 300215: +17.0% average CAGR, $31.1B calculated opportunity.
- HS 300220: +16.3% average CAGR, $8.6B calculated opportunity.
- HS 330499: +16.2% average CAGR, $4.4B calculated opportunity.
- HS 300212: +10.7% average CAGR, $4.3B calculated opportunity.
- HS 382499: +8.3% average CAGR, $7.8B calculated opportunity.

## Diversification opportunities

- HS 300490: 7 buyer markets, $34.5B calculated opportunity.
- HS 330300: 5 buyer markets, $5.6B calculated opportunity.
- HS 330499: 5 buyer markets, $4.4B calculated opportunity.
- HS 382499: 4 buyer markets, $7.8B calculated opportunity.
- HS 382200: 3 buyer markets, $2.7B calculated opportunity.
- HS 300290: 3 buyer markets, $2.4B calculated opportunity.
- HS 300215: 2 buyer markets, $31.1B calculated opportunity.
- HS 300220: 2 buyer markets, $8.6B calculated opportunity.
- HS 330590: 2 buyer markets, $755.4M calculated opportunity.
- HS 300214: 1 buyer markets, $4.9B calculated opportunity.

## Method

Reported trade observations and calculated indicators are shown separately. Validate buyers, standards, logistics, pricing, and competition before acting. [Read the Yugalinks methodology](https://www.yugalinks.com/methodology).

## Data sources

- Primary trade series: OECD (2025), Balanced international merchandise trade statistics (BIMTS) - HS2017-6D, OECD Data Explorer (accessed on 2026-08-30). [OECD Data Explorer](https://data-explorer.oecd.org/) - [OECD Terms & Conditions](https://www.oecd.org/termsandconditions/)
- CEPII BACI bilateral trade flows (202601): [dataset page](https://www.cepii.fr/CEPII/en/bdd_modele/bdd_modele_item.asp?id=37) - [BACI documentation](https://www.cepii.fr/DATA_DOWNLOAD/baci/doc/baci_webpage.html) - [Etalab 2.0 Open Licence](https://www.etalab.gouv.fr/wp-content/uploads/2018/11/open-licence.pdf)

This page presents derived Yugalinks views of reported observations and calculated indicators.